Leukemia research · 2010
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rivero Ana, Rapado Inmaculada, Tomás José F, Montalbán Carlos, de Oña Raquel, Paz-Carreira José, Canales Miguel, Martínez Rafael, Sánchez-Godoy Pedro, de Sevilla Alberto Fernández, de la Serna Javier, Martínez-López Joaquín
Аннотация
DCK catalyzes the intracellular phosphorylation of fludarabine. The promoter and coding region of the DCK gene were analyzed in 74 follicular lymphoma (FL) patients receiving a therapeutic regimen that included fludarabine. DCK mRNA expression was quantified in a cohort of healthy donors. Four previously described genotypic variants, -360C>G, -201C>T (rs2306744), C28624T (rs11544786) and c.91+37G>C (rs9997790), as well as the new variant, -12C>G, were identified. Variant C28624T showed a lower risk of lymphopenia (P=0.04), but a higher risk of neutropenia (P=0.04). Statistical significance was found in bivariate logistic regression between lymphopenia and infectious episodes in the induction period (odds ratio 3.85, P=0.04).
Предметные рубрики MeSH
AllelesAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDNA Mutational AnalysisDeoxycytidine KinaseDrug-Related Side Effects and Adverse ReactionsGene Expression Regulation, EnzymologicGene Expression Regulation, LeukemicGene FrequencyGenotypeHumansKaplan-Meier EstimateLogistic ModelsLymphoma, FollicularLymphopeniaNeutropeniaPolymorphism, Single NucleotidePromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionTreatment OutcomeVidarabine